Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.

Cheng W, Chen Z, Li P, Zhang Y, Ma Y, Liu P, Jiang H

Frontiers in endocrinology15 Sept 2025Cited by 1 (Europe PMC)

PMID41030857PMCIDPMC12477040DOI10.3389/fendo.2025.1654506PepBankPUB-41030857

Summary

ObjectiveMazdutide, a glucagon-like peptide-1/glucagon receptor (GLP - 1/GCGR) dual agonist, has shown marked efficacy in glycemic control, weight loss, and metabolic improvement in adults. However, data in adolescents remain limited. This report explores its therapeutic potential in an adolescent with obesity-related type 2 diabetes mellitus (T2DM) and hyperuricemia (HUA).Study design and methodsWe report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L). The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.ResultsAfter 36 weeks, the patient showed significant improvement: weight decreased by 16.8 kg (18.89% BMI reduction), uric acid dropped by 37.00%, and HbA1c fell by 21.88%. No hypoglycemic episodes occurred. Lipid levels improved notably: triglycerides fell by 69.02%, total cholesterol by 13.65%, and LDL cholesterol by 17.27%. Hepatic steatosis resolved by week 14, as confirmed by ultrasound. No adverse events were reported, and benefits were sustained post-treatment.ConclusionsMazdutide exhibited robust metabolic efficacy and good tolerability in an adolescent with obesity, T2DM, and HUA. It improved glycemic control, reduced weight and uric acid, reversed steatosis, and modulated lipid profiles. These findings support its potential as a comprehensive treatment for adolescent metabolic disorders.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Mazdutide.

01HumanNot a test of Mazdutide aloneCase report or seriesEfficacy outcome
In a 15-year-old with obesity, type 2 diabetes and hyperuricemia, body weight fell by 16.8 kg after 36 weeks of mazdutide with metformin and insulin.
In plain wordsIn one teenager with obesity, diabetes and high uric acid, weight fell by 16.8 kg over 36 weeks of mazdutide plus other drugs.
Peptide
Mazdutide
Outcome
DecreaseBody weight change after 36 weeks
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−16.8 kg
36 weeks
Source sentences
Summary
After 36 weeks, the patient showed significant improvement: weight decreased by 16.8 kg
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L).
Summary · context
The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Show in the study text Report a problemFND-4103085701
02HumanNot a test of Mazdutide aloneCase report or seriesEfficacy outcome
In a 15-year-old with obesity, type 2 diabetes and hyperuricemia, BMI fell by 18.89% after 36 weeks of mazdutide with metformin and insulin.
In plain wordsIn one teenager with obesity, diabetes and high uric acid, BMI fell by 18.89% over 36 weeks of mazdutide plus other drugs.
Peptide
Mazdutide
Outcome
DecreaseBMI reduction
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Measurements
BMI reduction
18.89%
36 weeks
Source sentences
Summary
After 36 weeks, the patient showed significant improvement: weight decreased by 16.8 kg (18.89% BMI reduction)
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L).
Summary · context
The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Show in the study text Report a problemFND-4103085702
03HumanNot a test of Mazdutide aloneCase report or seriesEfficacy outcome
In a 15-year-old with obesity, type 2 diabetes and hyperuricemia, uric acid dropped by 37.00% after 36 weeks of mazdutide with metformin and insulin.
In plain wordsIn one teenager with obesity, diabetes and high uric acid, uric acid dropped by 37.00% over 36 weeks of mazdutide plus other drugs.
Peptide
Mazdutide
Outcome
DecreaseSerum uric acid change
Study
n = 1
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Measurements
Uric acid change
−37%
36 weeks
Source sentences
Summary
After 36 weeks, the patient showed significant improvement
3 context sentences(design, population, supporting numbers)
Summary · context
uric acid dropped by 37.00%, and HbA1c fell by 21.88%.
Summary · context
We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L).
Summary · context
The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Show in the study text Report a problemFND-4103085703
04HumanNot a test of Mazdutide aloneCase report or seriesEfficacy outcome
In a 15-year-old with obesity, type 2 diabetes and hyperuricemia, HbA1c fell by 21.88% after 36 weeks of mazdutide with metformin and insulin.
In plain wordsIn one teenager with obesity, diabetes and high uric acid, HbA1c fell by 21.88% over 36 weeks of mazdutide plus other drugs.
Peptide
Mazdutide
Outcome
DecreaseHbA1c change
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−21.88%
36 weeks
Source sentences
Summary
After 36 weeks, the patient showed significant improvement
3 context sentences(design, population, supporting numbers)
Summary · context
HbA1c fell by 21.88%.
Summary · context
We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L).
Summary · context
The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Show in the study text Report a problemFND-4103085704
05HumanNot a test of Mazdutide aloneCase report or seriesSafety outcome
In a 15-year-old with obesity, type 2 diabetes and hyperuricemia, no hypoglycemic episodes occurred during mazdutide treatment with metformin and insulin.
In plain wordsIn one teenager treated with mazdutide plus other drugs, no low blood sugar episodes occurred.
Peptide
Mazdutide
Outcome
No significant changeHypoglycemic episodes
Study
n = 1
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
No hypoglycemic episodes occurred.
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L).
Summary · context
The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Show in the study text Report a problemFND-4103085705
06HumanNot a test of Mazdutide aloneCase report or seriesEfficacy outcome
In a 15-year-old with obesity, type 2 diabetes and hyperuricemia, triglycerides fell by 69.02% with mazdutide plus metformin and insulin.
In plain wordsIn one teenager treated with mazdutide plus other drugs, triglycerides fell by 69.02%.
Peptide
Mazdutide
Outcome
DecreaseTriglycerides change
Study
n = 1
Outcome group
Lipids · Metabolic and weight
Measurements
Triglycerides change
−69.02%
36 weeks
Source sentences
Summary
triglycerides fell by 69.02%
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L).
Summary · context
The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Show in the study text Report a problemFND-4103085706
07HumanNot a test of Mazdutide aloneCase report or seriesEfficacy outcome
In a 15-year-old with obesity, type 2 diabetes and hyperuricemia, total cholesterol fell by 13.65% with mazdutide plus metformin and insulin.
In plain wordsIn one teenager treated with mazdutide plus other drugs, total cholesterol fell by 13.65%.
Peptide
Mazdutide
Outcome
DecreaseTotal cholesterol change
Study
n = 1
Outcome group
Lipids · Metabolic and weight
Measurements
Total cholesterol change
−13.65%
36 weeks
Source sentences
Summary
Lipid levels improved notably: triglycerides fell by 69.02%, total cholesterol by 13.65%
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L).
Summary · context
The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Show in the study text Report a problemFND-4103085707
08HumanNot a test of Mazdutide aloneCase report or seriesEfficacy outcome
In a 15-year-old with obesity, type 2 diabetes and hyperuricemia, LDL cholesterol fell by 17.27% with mazdutide plus metformin and insulin.
In plain wordsIn one teenager treated with mazdutide plus other drugs, LDL cholesterol fell by 17.27%.
Peptide
Mazdutide
Outcome
DecreaseLDL cholesterol change
Study
n = 1
Outcome group
Lipids · Metabolic and weight
Measurements
LDL cholesterol change
−17.27%
36 weeks
Source sentences
Summary
Lipid levels improved notably: triglycerides fell by 69.02%, total cholesterol by 13.65%, and LDL cholesterol by 17.27%
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L).
Summary · context
The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Show in the study text Report a problemFND-4103085708
09HumanNot a test of Mazdutide aloneCase report or seriesEfficacy outcome
In a 15-year-old with obesity, type 2 diabetes and hyperuricemia, hepatic steatosis resolved by week 14 on ultrasound during mazdutide treatment with metformin and insulin.
In plain wordsIn one teenager treated with mazdutide plus other drugs, fatty liver resolved by week 14 on ultrasound.
Peptide
Mazdutide
Outcome
DecreaseHepatic steatosis by ultrasound
Study
n = 1
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Hepatic steatosis resolved by week 14, as confirmed by ultrasound.
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L).
Summary · context
The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Show in the study text Report a problemFND-4103085709
10HumanNot a test of Mazdutide aloneCase report or seriesSafety outcome
In a 15-year-old with obesity, type 2 diabetes and hyperuricemia, no adverse events were reported with mazdutide plus metformin and insulin.
In plain wordsIn one teenager treated with mazdutide plus other drugs, no side effects were reported.
Peptide
Mazdutide
Outcome
No significant changeAdverse events
Study
n = 1
Outcome group
Adverse events · Whole body
Source sentences
Summary
No adverse events were reported
2 context sentences(design, population, supporting numbers)
Summary · context
We report the case of a 15-year-old male patient diagnosed with obesity (BMI: 30.64 kg/m²), type 2 diabetes mellitus (HbA1c: 9.60%), and hyperuricemia (serum uric acid: 511 μmol/L).
Summary · context
The patient underwent a dose-escalation regimen of Mazdutide (2 mg → 4 mg → 6 mg, administered subcutaneously once weekly) in combination with metformin and insulin to evaluate therapeutic efficacy and safety outcomes.
In this study, Mazdutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Mazdutide.
Show in the study text Report a problemFND-4103085710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.